Author:
Wang Tzu-Fei,Mallick Ranjeeta,Noureldin Abdelrahman,Pecarskie Amanda,Carrier Marc,Auer Rebecca
Reference8 articles.
1. The effect of low-molecular-weight heparin on cancer survival;Lazo-Langner;A systematic review and meta-analysis of randomized trials, J Thromb Haemost,2007
2. R.C. Auer, M. Ott, P. Karanicolas, M.R. Brackstone, S. Ashamalla, J. Weaver, V. Tagalakis, M. Boutros, P. Stotland, A.C. Marulanda, H. Moloo, S. Jayaraman, S. Patel, G. Le Gal, S. Spadafora, S. MacLellan, D. Trottier, D. Jonker, T. Asmis, R. Mallick, A. Pecarskie, T. Ramsay, M. Carrier, P.-. investigators, Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial, BMJ 378 (2022) e071375.
3. Standardization Committee of the International Society on, Haemostasis, definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients;S. Schulman, C. Kearon, S. Subcommittee on Control of Anticoagulation of the, T;J. Thromb. Haemost.,2005
4. Subcommittee on control of, definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH;Kaatz;J. Thromb. Haemost.,2015
5. Heparanase in Cancer metastasis - heparin as a potential inhibitor of cell adhesion molecules;Bendas;Adv. Exp. Med. Biol.,2020